Product
CAR T-cell
2 clinical trials
14 indications
Indication
B-cell acute lymphoblastic leukemiaIndication
Diffuse Large B-Cell LymphomaIndication
B acute lymphoblastic leukemiaIndication
DLBCL with CIIndication
DLBCL UnclassifiableIndication
Noonan syndromeIndication
Diffuse Large B-cell LymphomaIndication
HGBLIndication
NOSIndication
Non-Hodgkin lymphomaIndication
RelapsedIndication
Non-Hodgkin's LymphomaClinical trial
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients With Relapsed or Refractory B-Cell LymphomasStatus: Recruiting, Estimated PCD: 2025-10-01